At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 149 enrolled
Drug / intervention
Duloxetinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia
In Brief
A Phase 3 clinical trial evaluating Duloxetine for Fibromyalgia. Completed, enrolled 149 participants across 1 site.
Detailed Summary
The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesJapan
CollaboratorsShionogi
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionFeb 2014
TodayJul 2026
First PostedJun 18, 2012
Enrollment StartJun 1, 2012
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.0 years ago
Interventions
Duloxetinedrug
Administered Orally